The Certara Blog: PBPK Modeling & Simulation

Predicting mAb Pharmacokinetics in Humans with a Minimal PBPK Model

Predicting mAb Pharmacokinetics in Humans with a Minimal PBPK Model

Monoclonal antibodies (mAbs) and their derivatives are a rapidly growing segment of the pharmaceutical industry’s pipeline. In fact, more than 40 mAbs and derivatives have been approved for a variety of therapeutic applications; around 500 mAbs and derivatives are currently in different stages of development. Monoclonal antibodies have pharmacokinetic (PK) properties that are quite distinct from that […]

Read More
Positive Stats About PK/PD Modeling in the Pharmaceutical Industry

Positive Stats About PK/PD Modeling in the Pharmaceutical Industry

Pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation (M&S) is an important tool that can help researchers gain a better understanding of their drug’s efficacy— especially at the early stages of drug development. In this blog post, I’ll discuss some positive statistics uncovered in a recent IQ Consortium survey that examined the current landscape for preclinical PK/PD modeling […]

Read More
5 Updates to the Simcyp Simulator You’ll Be Psyched About

5 Updates to the Simcyp Simulator You’ll Be Psyched About

The Simcyp™ Population-based Simulator streamlines drug development through the modelling and simulation of physiologically-based pharmacokinetics (PK) and pharmacodynamics (PD) in virtual patient populations. It incorporates numerous databases containing human physiological, genetic and epidemiological information. By integrating this information with in vitro or clinical data, the Simulator can predict PK/PD behavior in ‘real-world’ populations. It can be used to select […]

Read More
PBPK Modeling and Simulation Discussed at the AAPS Annual Meeting

PBPK Modeling and Simulation Discussed at the AAPS Annual Meeting

I recently got the chance to attend the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego, California. It was a valuable opportunity to see some truly innovative scientific approaches to the toughest challenges in drug development. Pediatric drug development, in particular, remains a top challenge for the pharmaceutical industry as […]

Read More
Reasons to Attend Certara’s CADD, PK/PD, and PBPK Modeling Courses

Reasons to Attend Certara’s CADD, PK/PD, and PBPK Modeling Courses

As the manager of scientific communication for Certara, part of my job is to educate new and existing clients on the ways they can maximize their utilization of Certara’s software and consulting services. Therefore, it was important for me, early on, to experience our training solutions to better understand our clients’ perspectives. At Certara, we […]

Read More
How PBPK Modeling Will Make Drugs Safer, Cheaper, and More Effective

How PBPK Modeling Will Make Drugs Safer, Cheaper, and More Effective

Historically, drugs have been selected using various methods (eg, biological and chemical screens). Candidate drugs were often pushed into the clinic with only a rudimentary understanding of the link between drug exposure and resultant effect(s). As a consequence, drug development has been inefficient by relying on trial and error at the clinical stage, not to […]

Read More